Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood protein may predict success after gastric bypass

NCT ID NCT07241741

Knowledge-focused Sponsor: Istanbul University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether a blood marker called PTX3 can predict how well people do after gastric bypass surgery. Researchers followed 23 patients for 6 months after surgery, measuring weight loss, insulin resistance, and inflammation. The goal was to see if PTX3 levels before surgery could forecast these outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors identify which patients will benefit most from bariatric surgery based on a simple blood test.
What could go wrong
This is a small, completed study with only 23 participants, so results may not apply to everyone. The findings are exploratory and need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

23 people

The number who actually took part.

Started

Jan 2015

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with obesity scheduled to undergo primary Roux-en-Y gastric bypass at Istanbul University Hospital. Sexes Eligible for Study: All Gender-Based: No Accepts Healthy Volunteers: No

Ages

18 to 65 days

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age: 18-65 years * Body mass index (BMI) ≥40 kg/m², or BMI ≥35 kg/m² with obesity-related comorbidity * Eligible for primary Roux-en-Y gastric bypass * Able to provide written informed consent Exclusion Criteria: * Previous bariatric surgery * Severe hepatic, renal, or cardiac failure * Active infection or inflammatory disease * Malignancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for C-reactive protein are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome Inflammation inflammatory disease Insulin Resistance metabolic syndrome X Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

C-reactive protein Chronic inflammation Inflammation Insulin resistance Interleukin-6 Metabolic syndrome Obesity Roux-en Y gastric bypass

More trials for these conditions

Other studies related to the condition(s) this trial covers.